Merck & Co., Inc. Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31)
Merck & Co., Inc. (MRK) reported Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) of $21.00 million for the 6-month period ending 2013-06-30, per its 10-Q filed 2013-08-07.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax · last filed 2013-08-07
- Merck & Co., Inc. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for the quarter ending 2013-06-30 was $1.00M.
- Merck & Co., Inc. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for the quarter ending 2013-03-31 was $20.00M.
- Merck & Co., Inc. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for fiscal 2012 was $20.00M, a 60.00% decline from fiscal 2011.
- Merck & Co., Inc. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for fiscal 2011 was $50.00M, a 1150.00% increase from fiscal 2010.
- Merck & Co., Inc. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for fiscal 2010 was $4.00M.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) 6 month | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) 12 month |
|---|---|---|---|
| 2013-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | $21.00M 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $20.00M 10-Q · filed 2013-05-09 | ||
| 2012-12-31 | $20.00M 10-K · filed 2013-02-28 | ||
| 2011-12-31 | $50.00M 10-K · filed 2013-02-28 | ||
| 2010-12-31 | $4.00M 10-K · filed 2013-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |